Characterization of AAV-mediated dorsal root ganglionopathy
Open accessAbstract
Recent studies in non-human primates administered recombinant adeno-associated viruses (rAAVs) have shown lesions in the dorsal root ganglia (DRG) of unknown pathogenesis. In this study, rAAV9s manufactured using different purification methods alongside a non-expressing Null AAV9 vector was administered to groups of cynomolgus monkeys followed by neuropathological evaluation after 4 weeks. Lesions, including neuronal degeneration, increased cellularity, and nerve fiber degeneration, were observed in the DRG, regardless of purification methods. Animals did not develop any neurological signs throughout the study, and there was no loss of function observed in neuro-electrophysiological endpoints or clear effects on intraepidermal nerve fiber density. However, magnetic resonance imaging (MRI) of animals with axonopathy showed an increase in short tau inversion recovery (STIR) intensity and decrease in fractional anisotropy. In animals administered the Null AAV9 vector, DRG lesions were not observed despite vector DNA being detected in the DRG at levels equivalent to or greater than rAAV9-treated animals. This study further supports that DRG toxicity is associated with transgene overexpression in DRGs, with particular sensitivity at the lumbar and lumbosacral level. The data from this study also showed that the nerve fiber degeneration did not correlate with any functional effect on nerve conduction but was detectable by MRI.
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
AAV-mediated gene delivery into the CNS of pigs or non-human primates causes dorsal root ganglion toxicity that is alleviated by reducing or deleting transgene expression.
“For example, AAV-mediated gene delivery into the CNS of pigs or non-human primates causes dorsal root ganglion toxicity that is alleviated by reducing or deleting transgene expression.38,39,66”
From An innate immune response to adeno-associated virus genomes decreases cortical dendritic complexity and disrupts synaptic transmission (2024) · cites this paper as [66]
AAV-mediated gene delivery has been associated with neurotoxicity in specific cell populations, some of which can be attributed to the overexpressed transgene.
“Despite an overall strong safety profile, AAV-mediated gene delivery has been associated with neurotoxicity in specific cell populations, some of which can be attributed to the overexpressed transgene.”
From An innate immune response to adeno-associated virus genomes decreases cortical dendritic complexity and disrupts synaptic transmission (2024) · cites this paper as [66]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Cites
Hinderer, C., Katz, N., Buza, E. L., Dyer, C., Goode, T., Bell, P., Richman, L. K., & Wilson, J. M. (2018) · Human Gene Therapy · doi:10.1089/hum.2018.015 · Cited by 814 · see citing works
Current clinical applications of in vivo gene therapy with AAVs
Mendell, J. R., Al-Zaidy, S. A., Rodino-Klapac, L. R., Goodspeed, K., Gray, S. J., Kay, C. N., Boye, S. L., Boye, S. E., George, L. A., Salabarria, S., et al. (2021) · Molecular Therapy · doi:10.1016/j.ymthe.2020.12.007 · Cited by 743 · see citing works
The clinical landscape for AAV gene therapies
Kuzmin, D. A., Shutova, M. V., Johnston, N. R., Smith, O. P., Fedorin, V. V., Kukushkin, Y. S., van der Loo, J. C. M., & Johnstone, E. C. (2021) · Nature Reviews Drug Discovery · doi:10.1038/d41573-021-00017-7 · Cited by 503 · see citing works
Day, J. W., Finkel, R. S., Chiriboga, C. A., Connolly, A. M., Crawford, T. O., Darras, B. T., Iannaccone, S. T., Kuntz, N. L., Peña, L. D. M., Shieh, P. B., et al. (2021) · The Lancet Neurology · doi:10.1016/s1474-4422(21)00001-6 · Cited by 494 · see citing works
Applications of diffusion‐weighted and diffusion tensor MRI to white matter diseases – a review
Horsfield, M. A., & Jones, D. K. (2002) · NMR in Biomedicine · doi:10.1002/nbm.787 · Cited by 468 · see citing works
Denervated human skeletal muscle: MR imaging evaluation.
Fleckenstein, J. L., Watumull, D., Conner, K. E., Ezaki, M., Greenlee, R. G., Bryan, W. W., Chason, D. P., Parkey, R. W., Peshock, R. M., & Purdy, P. D. (1993) · Radiology · doi:10.1148/radiology.187.1.8451416 · Cited by 368 · see citing works
Mendell, J. R., Al-Zaidy, S. A., Lehman, K. J., McColly, M., Lowes, L. P., Alfano, L. N., Reash, N. F., Iammarino, M. A., Church, K. R., Kleyn, A., et al. (2021) · JAMA Neurology · doi:10.1001/jamaneurol.2021.1272 · Cited by 295 · see citing works
Meyer, K., Ferraiuolo, L., Schmelzer, L., Braun, L., McGovern, V., Likhite, S., Michels, O., Govoni, A., Fitzgerald, J., Morales, P., et al. (2015) · Molecular Therapy · doi:10.1038/mt.2014.210 · Cited by 286 · see citing works
<i>SOD1</i> Suppression with Adeno-Associated Virus and MicroRNA in Familial ALS
Mueller, C., Berry, J. D., McKenna-Yasek, D. M., Gernoux, G., Owegi, M. A., Pothier, L. M., Douthwright, C. L., Gelevski, D., Luppino, S. D., Blackwood, M., et al. (2020) · New England Journal of Medicine · doi:10.1056/nejmoa2005056 · Cited by 264 · see citing works
Adeno-Associated Virus-Induced Dorsal Root Ganglion Pathology
Hordeaux, J., Buza, E. L., Dyer, C., Goode, T., Mitchell, T. W., Richman, L., Denton, N., Hinderer, C., Katz, N., Schmid, R., et al. (2020) · Human Gene Therapy · doi:10.1089/hum.2020.167 · Cited by 257 · see citing works
AAV <i>cis</i> -regulatory sequences are correlated with ocular toxicity
Xiong, W., Wu, D. M., Xue, Y., Wang, S. K., Chung, M. J., Ji, X., Rana, P., Zhao, S. R., Mai, S., & Cepko, C. L. (2019) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1821000116 · Cited by 249 · see citing works
MRI of normal and pathologic skeletal muscle
Murphy, W. A., Totty, W. G., & Carroll, J. E. (1986) · American Journal of Roentgenology · doi:10.2214/ajr.146.3.565 · Cited by 168 · see citing works
Samaranch, L., Sebastián, W. S., Kells, A. P., Salegio, E. A., Heller, G., Bringas, J. R., Pivirotto, P., DeArmond, S. J., Forsayeth, J., & Bankiewicz, K. S. (2013) · Molecular Therapy · doi:10.1038/mt.2013.266 · Cited by 157 · see citing works
Shao, W., Earley, L. F., Chai, Z., Chen, X., Sun, J., He, T., Deng, M., Hirsch, M. L., Ting, J., Samulski, R. J., et al. (2018) · JCI Insight · doi:10.1172/jci.insight.120474 · Cited by 119 · see citing works
Hordeaux, J., Hinderer, C., Goode, T., Katz, N., Buza, E. L., Bell, P., Calcedo, R., Richman, L. K., & Wilson, J. M. (2018) · Molecular Therapy - Methods & Clinical Development · doi:10.1016/j.omtm.2018.06.003 · Cited by 105 · see citing works
Eguchi, Y., Ohtori, S., Orita, S., et al. (2011) · American Journal of Neuroradiology · doi:10.3174/ajnr.a2681 · Cited by 98 · see citing works
Hordeaux, J., Hinderer, C., Goode, T., Buza, E. L., Bell, P., Calcedo, R., Richman, L. K., & Wilson, J. M. (2018) · Molecular Therapy - Methods & Clinical Development · doi:10.1016/j.omtm.2018.06.004 · Cited by 81 · see citing works
Hordeaux, J., Hinderer, C. J., Buza, E. L., Louboutin, J., Jahan, T., Bell, P. L., Chichester, J. A., Tarantal, A. F., & Wilson, J. M. (2019) · Human Gene Therapy · doi:10.1089/hum.2019.012 · Cited by 76 · see citing works
Qu, W., Wang, M., Wu, Y., & Xu, R. (2015) · Current Pharmaceutical Biotechnology · doi:10.2174/1389201016666150505122228 · Cited by 75 · see citing works
Rieser, R., Koch, J., Faccioli, G., Richter, K., Menzen, T., Biel, M., Winter, G., & Michalakis, S. (2021) · Pharmaceutics · doi:10.3390/pharmaceutics13050748 · Cited by 62 · see citing works
Development challenges associated with rAAV-based gene therapies
Bolt, M. W., Brady, J. T., Whiteley, L. O., & Khan, K. N. M. (2021) · The Journal of Toxicological Sciences · doi:10.2131/jts.46.57 · Cited by 43 · see citing works
Rosenberg, J. B., Chen, A., De, B. P., Dyke, J. P., Ballon, D. J., Monette, S., Ricart Arbona, R. J., Kaminsky, S. M., Crystal, R. G., & Sondhi, D. (2021) · Human Gene Therapy · doi:10.1089/hum.2020.269 · Cited by 41 · see citing works
Buschbacher's Manual of Nerve Conduction Studies
Buschbacher, R. M., Kumbhare, D. A., & Robinson, L. R. (2015) · Medical Entomology and Zoology · Cited by 34 · see citing works
A pilot study assessing T1-weighted muscle MRI in amyotrophic lateral sclerosis (ALS)
Diamanti, L., Alfonsi, E., Ferraro, O. E., Cereda, C., Pansarasa, O., Bastianello, S., & Pichiecchio, A. (2018) · Skeletal Radiology · doi:10.1007/s00256-018-3073-7 · Cited by 22 · see citing works
Lakritz, J. R., Robinson, J. A., Polydefkis, M. J., Miller, A. D., & Burdo, T. H. (2015) · Journal of Neuroinflammation · doi:10.1186/s12974-015-0456-8 · Cited by 20 · see citing works
Ramsingh, A. I., Gray, S. J., Reilly, A. A., Koday, M., Bratt, D., Koday, M. T., Murnane, R. D., Smedley, J. V., Hu, Y., Messer, A. C., et al. (2018) · PLoS ONE · doi:10.1371/journal.pone.0198154 · Cited by 20 · see citing works
Pardo, I. D. R., Rao, D. B., Butt, M. T., Jortner, B. S., Valentine, W. M., Arezzo, J. C., Sharma, A. K., & Bolon, B. N. (2018) · Toxicologic Pathology · doi:10.1177/0192623318800707 · Cited by 17 · see citing works
Self-citationDaSilva, J. K., & Arezzo, J. C. (2019) · Toxicologic Pathology · doi:10.1177/0192623319873878 · Cited by 15 · see citing works
Field, A. S., Samsonov, A. A., Alexander, A. L., Mossahebi, P., & Duncan, I. D. (2018) · Journal of Magnetic Resonance Imaging · doi:10.1002/jmri.26300 · Cited by 9 · see citing works
Flagged first, then by citations
Cited by
Sorted by citations
Suriano, C. M., Kumar, N., Verpeut, J. L., Ma, J., Jung, C., Dunn, C. E., Carvajal, B. V., Nguyen, A. V., & Boulanger, L. M. (2024) · Molecular Therapy · doi:10.1016/j.ymthe.2024.03.036 · Cited by 21 · see citing works
- Authors
- Buss, N., Lanigan, L., Zeller, J., Cissell, D., Metea, M., Adams, E., Higgins, M., Kim, K. H., Budzynski, E., Yang, L., Liu, Y., Butt, M., Danos, O., & Fiscella, M.
- Affiliations
- Regenxbio (United States) (US)
- Invicro (United States) (US)
- Corresponding author
- Buss, Nicholas
- ORCID
- Venue
- Molecular Therapy - Methods & Clinical Development
- Publisher
- Elsevier BV
- Published
- 2022-03
- Volume
- 24
- Pages
- 342-354
- ISSN
- 2329-0501 (ISSN-L)
- PMC
- PMC8851102
- OpenAlex
- W4210418472
- Cited by
- 81
- References
- 29
- Citations by year
- 2026: 16 · 2025: 16 · 2024: 21 · 2023: 20 · 2022: 8
- FWCI
- 9.80
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- Locations
- Molecular Therapy — Methods & Clinical Development (publishedVersion, cc-by-nc-nd)
- PubMed Central (publishedVersion, cc-by-nc-nd)
- PubMed (publishedVersion)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- Funders
- REGENXBIO
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Genetics › Virus-based gene therapy research
- Health Sciences › Medicine › Physiology › Pain Mechanisms and Treatments
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › RNA Interference and Gene Delivery
- Keywords
- adeno-associated virus, AAV9, dorsal root ganglia, transgenic overexpression, neurodegeneration, nerve fiber degeneration, axonopathy, fractional anisotropy, STIR MRI, Macaca fascicularis, intraepidermal nerve fibers, nerve conduction
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
